FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to								
Section 16. Form 4 or Form 5								
obligations may continue. See								
Instruction 1(b).								

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol Verrica Pharmaceuticals Inc. [VRCA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
OCLASSEN GLENN A					CITICO	a i iidi	IIICIC	<u>cutreurs r</u>	iic. į viko	J. I. J	:	X Directo	or	10% Ov	vner		
(Last) (First) (Middle) C/O VERRICA PHARMACEUTICALS INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/14/2018							Officer below)	(give title	Other (s below)	specify		
10 NORTH HIGH STREET, SUITE 200						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable				
(Street) WEST CHESTE	CR PA	1	22902	4.	4. Il Ameriament, Date di Original Pilea (Montali				eu (Montribe	ay/ rear)	Line	X Form filed by One Reporting Person Form filed by More than One Reporting Person			n		
(City)	(Si	tate)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			Code (Ins	n Disposed	ties Acquired (A) or d Of (D) (Instr. 3, 4 and (A) or (D) Price		Beneficia	es Fo ally (D following (I) I ion(s)	orm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$ 15	06/14/2018		A		17,502		(1)	06/14/2028	Common Stock	17,502	\$0.00	17,502	D			

Explanation of Responses:

1. 1/3 of the total shares subject to the option shall vest on June 14, 2019 and 1/36th of the total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

/s/ Edward Sniezek, Attorney-

06/18/2018

in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.